{"id":745518,"date":"2017-07-24T06:00:00","date_gmt":"2017-07-24T06:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-results-from-oncemrk-a-study-evaluating-once-daily-isentress-hd-raltegravir-in-combination-with-other-antiretroviral-agents-for-the-treatment-of-hiv-1-infection-in-a\/"},"modified":"2025-11-07T01:26:22","modified_gmt":"2025-11-07T06:26:22","slug":"merck-announces-week-96-results-from-oncemrk-a-study-evaluating-once-daily-isentress-hd-raltegravir-in-combination-with-other-antiretroviral-agents-for-the-treatment-of-hiv-1-infection-in-a","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-results-from-oncemrk-a-study-evaluating-once-daily-isentress-hd-raltegravir-in-combination-with-other-antiretroviral-agents-for-the-treatment-of-hiv-1-infection-in-a\/","title":{"rendered":"Merck Announces Week 96 Results from ONCEMRK, A Study Evaluating Once-Daily ISENTRESS\u00ae HD (raltegravir), in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in Appropriate Patients"},"content":{"rendered":"<p class=\"bwalignc\">       Once-Daily Version of Raltegravir Now Approved in U.S. and European        Union     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the presentation of Week 96 results from the pivotal<br \/>\n      Phase 3 ONCEMRK study evaluating the efficacy and safety of ISENTRESS HD<sup>1<\/sup>,<br \/>\n      a 1200 mg once-daily dose of the company\u2019s integrase inhibitor, ISENTRESS<sup>\u00ae<\/sup><br \/>\n      (raltegravir), administered orally as two 600 mg film-coated tablets, in<br \/>\n      combination with other antiretroviral agents, for the treatment of HIV-1<br \/>\n      infection in adults and pediatric patients weighing at least 40 kg, who<br \/>\n      are treatment-na\u00efve or whose virus has been suppressed on an initial<br \/>\n      regimen of ISENTRESS 400 mg given twice daily. Previously, the findings<br \/>\n      at Week 48 demonstrated that once-daily ISENTRESS HD met its primary<br \/>\n      efficacy endpoint of non-inferiority to twice-daily ISENTRESS, with a<br \/>\n      similar safety and tolerability profile. The Week 96 results reaffirm<br \/>\n      the comparable efficacy and safety of ISENTRESS HD. These study results<br \/>\n      were presented today during a late-breaking abstract session at the 9th<br \/>\n      International Conference on HIV Science (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ias2017.org%2F&amp;esheet=51593632&amp;newsitemid=20170724005286&amp;lan=en-US&amp;anchor=IAS+2017&amp;index=1&amp;md5=11d676bac2eb282393b1e7818b53502e\" rel=\"nofollow\">IAS<br \/>\n      2017<\/a>) being held in Paris, France, from July 23-26, 2017.\n    <\/p>\n<p>\n      \u201cThe Week 96 results from the ONCEMRK trial reinforce the findings from<br \/>\n      the 48-week analysis and support the use of ISENTRESS HD, in combination<br \/>\n      with other antiretroviral agents, as a once-a-day treatment option for<br \/>\n      some people living with HIV,\u201d said Dr. Pedro Cahn, chief of the<br \/>\n      infectious disease unit at Juan A. Fernandez Hospital, Buenos Aires,<br \/>\n      Argentina, and lead study investigator.\n    <\/p>\n<p>\n      ISENTRESS and ISENTRESS HD do not cure HIV-1 infection or AIDS. Severe,<br \/>\n      potentially life-threatening and fatal skin reactions have been<br \/>\n      reported. This includes cases of Stevens-Johnson syndrome,<br \/>\n      hypersensitivity reaction, and toxic epidermal necrolysis. Immediately<br \/>\n      discontinue treatment with ISENTRESS or ISENTRESS HD and other suspect<br \/>\n      agents if severe hypersensitivity, severe rash, or rash with systemic<br \/>\n      symptoms or liver aminotransferase elevations develop and monitor<br \/>\n      clinical status, including liver aminotransferases closely. For more<br \/>\n      information, see \u201cSelected Safety Information\u201d below.\n    <\/p>\n<p>\n      Week 96 data from the ONCEMRK study showed that 81.5 percent of the 531<br \/>\n      patients taking once-daily ISENTRESS HD 1200 mg (2 x 600 mg) achieved<br \/>\n      viral suppression of less than 40 copies\/mL of HIV-1 RNA, compared to<br \/>\n      80.1 percent of the 266 patients taking twice-daily ISENTRESS 400 mg,<br \/>\n      both in combination therapy with emtricitabine plus tenofovir disoproxil<br \/>\n      fumarate, with a treatment difference of 1.4 percent (95 percent<br \/>\n      confidence interval -4.4, 7.3). Increases in CD4+T-cell counts from<br \/>\n      baseline were comparable for the two treatment regimens, with an average<br \/>\n      increase of 261.6 cells\/mm<sup>3<\/sup> for once-daily ISENTRESS HD and<br \/>\n      262.2 cells\/mm<sup>3<\/sup> for twice-daily ISENTRESS. Efficacy was<br \/>\n      consistent across a variety of patient populations, including those with<br \/>\n      high viral load at baseline (HIV-1 RNA &gt;100,000 copies\/mL).\n    <\/p>\n<p>\n      Treatment-emergent viral mutations leading to any drug resistance were<br \/>\n      detected in less than 1 percent of patients in both treatment arms, with<br \/>\n      4\/531 (0.8 percent) in the once-daily ISENTRESS HD treatment arm, and<br \/>\n      2\/266 (0.8 percent) in the twice-daily ISENTRESS treatment arm through<br \/>\n      96 weeks. The rate of discontinuation of therapy due to adverse events<br \/>\n      through 96 weeks was low (1.3 percent in patients receiving once-daily<br \/>\n      ISENTRESS HD and 2.3 percent in patients receiving twice-daily<br \/>\n      ISENTRESS).\n    <\/p>\n<p>\n      In the United States, once-daily ISENTRESS HD was approved by the Food<br \/>\n      and Drug Administration (FDA) on May 26, 2017, in combination with other<br \/>\n      antiretroviral agents, for the treatment of HIV-1 infection in adults,<br \/>\n      and pediatric patients weighing at least 40 kg, who are treatment-na\u00efve<br \/>\n      or whose virus has been suppressed on an initial regimen of ISENTRESS<br \/>\n      400 mg given twice daily. ISENTRESS HD is administered as a 1200 mg<br \/>\n      once-daily dose, given orally as two 600 mg film-coated tablets.\n    <\/p>\n<p>\n      On July 13, 2017, the European Commission granted marketing<br \/>\n      authorization for once-daily ISENTRESS 600 mg in the European Union, to<br \/>\n      be administered as a once-daily 1200 mg oral dose given as two 600 mg<br \/>\n      tablets, in combination therapy with other antiretroviral medicinal<br \/>\n      products, for the treatment of HIV-1 infection in adults and pediatric<br \/>\n      patients weighing at least 40 kg, who are treatment-na\u00efve or whose virus<br \/>\n      has been suppressed on an initial regimen of ISENTRESS 400 mg twice<br \/>\n      daily. Regulatory reviews are underway for once-daily version of<br \/>\n      ISENTRESS in other countries and regions around the world, including<br \/>\n      Australia and Switzerland.\n    <\/p>\n<p>\n      <b>About ONCEMRK<\/b>\n    <\/p>\n<p>\n      The ONCEMRK study is a Phase 3 multicenter, double-blind, randomized,<br \/>\n      active comparator-controlled clinical trial designed to evaluate the<br \/>\n      efficacy and safety of once-daily ISENTRESS HD 1200 mg (given as two 600<br \/>\n      mg oral tablets), compared to twice-daily ISENTRESS 400 mg, each in<br \/>\n      combination therapy with emtricitabine plus tenofovir disoproxil<br \/>\n      fumarate in previously untreated adults with HIV-1 infection with levels<br \/>\n      of HIV-1 RNA \u2265 1,000 copies\/mL. The primary efficacy objective was the<br \/>\n      proportion of participants achieving less than 40 copies\/mL of HIV-1 RNA<br \/>\n      at Week 48, with a planned total treatment duration of 96 weeks. The<br \/>\n      non-inferiority margin was 10 percentage points.\n    <\/p>\n<p>\n      <b>Selected Safety Information about ISENTRESS HD (raltegravir) and<br \/>\n      ISENTRESS (raltegravir)<\/b>\n    <\/p>\n<p>\n      Immune reconstitution syndrome can occur, including the occurrence of<br \/>\n      autoimmune disorders with variable time to onset, which may necessitate<br \/>\n      further evaluation and treatment.\n    <\/p>\n<p>\n      ISENTRESS chewable tablets contain phenylalanine, a component of<br \/>\n      aspartame, which may be harmful to patients with phenylketonuria.\n    <\/p>\n<p>\n      Co-administration of ISENTRESS or ISENTRESS HD with drugs that induce<br \/>\n      uridine diphosphate glucuronosyltransferase (UGT) 1A1 may result in<br \/>\n      reduced plasma concentrations of raltegravir. Co-administration of<br \/>\n      ISENTRESS or ISENTRESS HD with drugs that inhibit UGT1A1 may increase<br \/>\n      plasma levels of raltegravir.\n    <\/p>\n<p>\n      Co-administration of ISENTRESS or ISENTRESS HD and other drugs may alter<br \/>\n      the plasma concentration of raltegravir. The potential for drug-drug<br \/>\n      interactions must be considered prior to and during therapy.<b> <\/b>Co-administration<br \/>\n      or staggered administration of aluminum and\/or magnesium<br \/>\n      hydroxide-containing antacids and ISENTRESS or ISENTRESS HD is not<br \/>\n      recommended. Co-administration of ISENTRESS HD with calcium carbonate<br \/>\n      antacids, tipranavir\/ritonavir, or etravirine is also not recommended.\n    <\/p>\n<p>\n      During co-administration with rifampin, the recommended dosage of<br \/>\n      ISENTRESS in adults is 800 mg twice daily. Rifampin, a strong inducer of<br \/>\n      UGT1A1, reduces plasma concentrations of ISENTRESS. There are no data to<br \/>\n      guide co-administration of ISENTRESS with rifampin in patients below 18<br \/>\n      years of age.\n    <\/p>\n<p>\n      Co-administration with rifampin is not recommended with ISENTRESS HD.\n    <\/p>\n<p>\n      The impact of other strong inducers of drug metabolizing enzymes on<br \/>\n      raltegravir is unknown (e.g., Carbamazepine, Phenobarbital, and<br \/>\n      Phenytoin). Co-administration of ISENTRESS or ISENTRESS HD with other<br \/>\n      strong inducers is not recommended.\n    <\/p>\n<p>\n      <b>About ISENTRESS (raltegravir)<\/b>\n    <\/p>\n<p>\n      Approved in 2007, ISENTRESS was the first integrase inhibitor developed<br \/>\n      for the treatment of HIV-1 infection.<b> <\/b>ISENTRESS is one of the<br \/>\n      regimen options recommended by the Department of Health and Human<br \/>\n      Services \u2013 in combination with other antiretroviral agents \u2013 as a<br \/>\n      first-line therapy in treatment-na\u00efve HIV-1 infected adults. ISENTRESS<br \/>\n      chewable tablets and oral suspension, each in combination therapy, are<br \/>\n      approved to treat pediatric patients aged at least four weeks of age,<br \/>\n      and weighing less than 20 kg.\n    <\/p>\n<p>\n      ISENTRESS works by inhibiting the insertion of HIV-1 DNA into human DNA<br \/>\n      by the integrase enzyme and has demonstrated rapid antiviral activity.<br \/>\n      Inhibiting integrase from performing this essential function limits the<br \/>\n      ability of the virus to replicate and infect new cells.\n    <\/p>\n<p>\n      ISENTRESS is approved as part of combination therapy in 112 countries<br \/>\n      for treatment of HIV-1 infection in adult patients. ISENTRESS, in<br \/>\n      combination therapy, for use in children and adolescents with HIV-1 aged<br \/>\n      two years and older has also been approved for use in 69 countries, and<br \/>\n      ISENTRESS oral suspension for infants at least four weeks of age is<br \/>\n      approved for use in 33 countries.\n    <\/p>\n<p>\n      <b>Selected Safety Information about ISENTRESS HD (raltegravir) and<br \/>\n      ISENTRESS (raltegravir) Continued<\/b>\n    <\/p>\n<p>\n      The most commonly reported (\u22652 percent) drug-related clinical adverse<br \/>\n      reactions of moderate to severe intensity in treatment-na\u00efve adult<br \/>\n      patients receiving ISENTRESS compared with efavirenz were headache (4<br \/>\n      percent vs. 5 percent), insomnia (4 percent vs. 4 percent), nausea (3<br \/>\n      percent vs. 4 percent), dizziness (2 percent vs. 6 percent), and fatigue<br \/>\n      (2 percent vs. 3 percent), respectively. The most commonly reported (\u22652<br \/>\n      percent) clinical adverse reactions of all intensities (Mild, Moderate,<br \/>\n      and Severe) in treatment-na\u00efve adult patients receiving ISENTRESS HD<br \/>\n      compared with ISENTRESS through 48 weeks included abdominal pain,<br \/>\n      diarrhea, vomiting, and decreased appetite. Intensities were defined as<br \/>\n      follows: Mild (awareness of sign or symptom, but easily tolerated);<br \/>\n      Moderate (discomfort enough to cause interference with usual activity);<br \/>\n      or Severe (incapacitating with inability to work or do usual activity).\n    <\/p>\n<p>\n      Grade 2\u20134 creatine kinase laboratory abnormalities were observed in<br \/>\n      subjects treated with ISENTRESS or ISENTRESS HD. Myopathy and<br \/>\n      rhabdomyolysis have been reported with ISENTRESS. Use with caution in<br \/>\n      patients at increased risk of myopathy or rhabdomyolysis, such as<br \/>\n      patients receiving concomitant medications known to cause these<br \/>\n      conditions and patients with a history of rhabdomyolysis, myopathy, or<br \/>\n      increased serum creatine kinase.\n    <\/p>\n<p>\n      There is a pregnancy exposure registry that monitors pregnancy outcomes<br \/>\n      in women exposed to ISENTRESS or ISENTRESS HD during pregnancy.<br \/>\n      Healthcare providers are encouraged to register patients by calling the<br \/>\n      Antiretroviral Pregnancy Registry (APR) at 1-800-258-4263.\n    <\/p>\n<p>\n      Women infected with HIV-1 should be instructed not to breastfeed if they<br \/>\n      are receiving ISENTRESS or ISENTRESS HD due to the potential for HIV<br \/>\n      transmission.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttp-3A__vip2-msd.com\/merckcom-migrated_index.html%26d%3DDwMFAg%26c%3DqwStF0e4-YFyvjCeML3ehA%26r%3D43WFv0xfssOPLIJFWwJaCtuZP-WA7FNg1ctmnH0E1X8%26m%3DDHpei7g_ZmepRtxNRJHHv-Y6u96h9qt4CGXBXoVeNHM%26s%3DTdpLhkj8lNAacB5d2N37x6TqJaSuM8SSZnU2ce65J70%26e%3D&amp;esheet=51593632&amp;newsitemid=20170724005286&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=6aad26722388c1b25bf60b86e77d68ea\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and&nbsp;connect with us on&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__twitter.com_Merck%26d%3DDwMFAg%26c%3DqwStF0e4-YFyvjCeML3ehA%26r%3D43WFv0xfssOPLIJFWwJaCtuZP-WA7FNg1ctmnH0E1X8%26m%3DDHpei7g_ZmepRtxNRJHHv-Y6u96h9qt4CGXBXoVeNHM%26s%3DIvQ6LIh6zo3YQd5UUw3wWQl24guv8qRu3ebQ4FEDSV0%26e%3D&amp;esheet=51593632&amp;newsitemid=20170724005286&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=4126a721c1cf7e03da1e7944090e9c2f\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__www.facebook.com_MerckInvents_%26d%3DDwMFAg%26c%3DqwStF0e4-YFyvjCeML3ehA%26r%3D43WFv0xfssOPLIJFWwJaCtuZP-WA7FNg1ctmnH0E1X8%26m%3DDHpei7g_ZmepRtxNRJHHv-Y6u96h9qt4CGXBXoVeNHM%26s%3Di92dW4OUpkD9X1V0DzGtO1YcVLld0mJZD6UuvTX7TB0%26e%3D&amp;esheet=51593632&amp;newsitemid=20170724005286&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=add58a0dd46142da35baacc54d1f4be1\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__www.instagram.com_merck_%26d%3DDwMFAg%26c%3DqwStF0e4-YFyvjCeML3ehA%26r%3D43WFv0xfssOPLIJFWwJaCtuZP-WA7FNg1ctmnH0E1X8%26m%3DDHpei7g_ZmepRtxNRJHHv-Y6u96h9qt4CGXBXoVeNHM%26s%3Dm9Kd5TOz0ys4U2n5yGD5-97kQcssAquyFD-6BIvia08%26e%3D&amp;esheet=51593632&amp;newsitemid=20170724005286&amp;lan=en-US&amp;anchor=Instagram&amp;index=5&amp;md5=158a3450aae2f53479250b225e8dbfb3\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttp-3A__www.youtube.com_Merck%26d%3DDwMFAg%26c%3DqwStF0e4-YFyvjCeML3ehA%26r%3D43WFv0xfssOPLIJFWwJaCtuZP-WA7FNg1ctmnH0E1X8%26m%3DDHpei7g_ZmepRtxNRJHHv-Y6u96h9qt4CGXBXoVeNHM%26s%3Dd9oKyF1SteXZc_T8i8dOgy2FSgZOSa0YRySSCNoIJAg%26e%3D&amp;esheet=51593632&amp;newsitemid=20170724005286&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=c65d4a4d07cdcb8ee952675fe0694875\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__www.linkedin.com_company_merck%26d%3DDwMFAg%26c%3DqwStF0e4-YFyvjCeML3ehA%26r%3D43WFv0xfssOPLIJFWwJaCtuZP-WA7FNg1ctmnH0E1X8%26m%3DDHpei7g_ZmepRtxNRJHHv-Y6u96h9qt4CGXBXoVeNHM%26s%3DEtVk4YXzHYoFXGcbnP_U1ampzNAW8cXSSb45BudXt3c%26e%3D&amp;esheet=51593632&amp;newsitemid=20170724005286&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=e9fe94e02598941171d416bb067b9ae9\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2016 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttp-3A__www.sec.gov_%26d%3DDwMFAg%26c%3DqwStF0e4-YFyvjCeML3ehA%26r%3D43WFv0xfssOPLIJFWwJaCtuZP-WA7FNg1ctmnH0E1X8%26m%3DO8jhEp-nT1TSdpa_yG56i7hRJDQokNmq3YfxukY44g8%26s%3D1ESN_N5lMWF-y_13JQLzDA2UvkeYb6CupBRpqAptuiU%26e%3D&amp;esheet=51593632&amp;newsitemid=20170724005286&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=1d4be1ba37ab2faea070252284a4aedc\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for ISENTRESS (raltegravir) and<br \/>\n      ISENTRESS HD (raltegravir) at <\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fi%2Fisentress%2Fisentress_pi.pdf&amp;esheet=51593632&amp;newsitemid=20170724005286&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fi%2Fisentress%2Fisentress_pi.pdf&amp;index=9&amp;md5=df984ebaa5f7ce5e6ccf3e1be5aeac09\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/i\/isentress\/isentress_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>,<br \/>\n      Patient Information for ISENTRESS and ISENTRESS HD (raltegravir) at<span class=\"bwuline\"><br \/>\n      <\/span><br \/>\n<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fi%2Fisentress%2Fisentress_ppi.pdf&amp;esheet=51593632&amp;newsitemid=20170724005286&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fi%2Fisentress%2Fisentress_ppi.pdf&amp;index=10&amp;md5=a1017b3b6dec92b295ebd5bd59d1c5f3\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/i\/isentress\/isentress_ppi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<br \/>\n      The Instructions for Use also are available at <\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fi%2Fisentress%2Fisentress_ifu.pdf&amp;esheet=51593632&amp;newsitemid=20170724005286&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fi%2Fisentress%2Fisentress_ifu.pdf&amp;index=11&amp;md5=c5b3301ea54f30f8c75f0e2399e2e913\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/i\/isentress\/isentress_ifu.pdf<\/b><br \/>\n<\/a>\n    <\/p>\n<p>\n      <sup>1<\/sup> ISENTRESS HD is marketed outside of the U.S. as ISENTRESS<br \/>\n      600 mg\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20170724005286r2&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pam Eisele, 267-305-3558<br \/>or<br \/>Carmen de        Gourville, 267-664-0146<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Once-Daily Version of Raltegravir Now Approved in U.S. and European Union Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of Week 96 results from the pivotal Phase 3 ONCEMRK study evaluating the efficacy and safety of ISENTRESS HD1, a 1200 mg once-daily dose of the company\u2019s integrase inhibitor, ISENTRESS\u00ae (raltegravir), administered orally as two 600 mg film-coated tablets, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg, who are treatment-na\u00efve or whose virus has been suppressed on an initial regimen of ISENTRESS 400 mg given twice daily. Previously, the findings at Week 48 demonstrated that once-daily ISENTRESS HD met its primary efficacy endpoint of non-inferiority to twice-daily ISENTRESS, with a similar safety and tolerability profile. The Week 96 results reaffirm the comparable efficacy and safety of ISENTRESS HD. These study<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-745518","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Week 96 Results from ONCEMRK, A Study Evaluating Once-Daily ISENTRESS\u00ae HD (raltegravir), in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in Appropriate Patients - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-results-from-oncemrk-a-study-evaluating-once-daily-isentress-hd-raltegravir-in-combination-with-other-antiretroviral-agents-for-the-treatment-of-hiv-1-infection-in-a\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Week 96 Results from ONCEMRK, A Study Evaluating Once-Daily ISENTRESS\u00ae HD (raltegravir), in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in Appropriate Patients - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Once-Daily Version of Raltegravir Now Approved in U.S. and European Union Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of Week 96 results from the pivotal Phase 3 ONCEMRK study evaluating the efficacy and safety of ISENTRESS HD1, a 1200 mg once-daily dose of the company\u2019s integrase inhibitor, ISENTRESS\u00ae (raltegravir), administered orally as two 600 mg film-coated tablets, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg, who are treatment-na\u00efve or whose virus has been suppressed on an initial regimen of ISENTRESS 400 mg given twice daily. Previously, the findings at Week 48 demonstrated that once-daily ISENTRESS HD met its primary efficacy endpoint of non-inferiority to twice-daily ISENTRESS, with a similar safety and tolerability profile. The Week 96 results reaffirm the comparable efficacy and safety of ISENTRESS HD. These study\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-results-from-oncemrk-a-study-evaluating-once-daily-isentress-hd-raltegravir-in-combination-with-other-antiretroviral-agents-for-the-treatment-of-hiv-1-infection-in-a\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-week-96-results-from-oncemrk-a-study-evaluating-once-daily-isentress-hd-raltegravir-in-combination-with-other-antiretroviral-agents-for-the-treatment-of-hiv-1-infection-in-a\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-week-96-results-from-oncemrk-a-study-evaluating-once-daily-isentress-hd-raltegravir-in-combination-with-other-antiretroviral-agents-for-the-treatment-of-hiv-1-infection-in-a\\\/\",\"name\":\"Merck Announces Week 96 Results from ONCEMRK, A Study Evaluating Once-Daily ISENTRESS\u00ae HD (raltegravir), in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in Appropriate Patients - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-07-24T06:00:00+00:00\",\"dateModified\":\"2025-11-07T06:26:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-week-96-results-from-oncemrk-a-study-evaluating-once-daily-isentress-hd-raltegravir-in-combination-with-other-antiretroviral-agents-for-the-treatment-of-hiv-1-infection-in-a\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-week-96-results-from-oncemrk-a-study-evaluating-once-daily-isentress-hd-raltegravir-in-combination-with-other-antiretroviral-agents-for-the-treatment-of-hiv-1-infection-in-a\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-week-96-results-from-oncemrk-a-study-evaluating-once-daily-isentress-hd-raltegravir-in-combination-with-other-antiretroviral-agents-for-the-treatment-of-hiv-1-infection-in-a\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Week 96 Results from ONCEMRK, A Study Evaluating Once-Daily ISENTRESS\u00ae HD (raltegravir), in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in Appropriate Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Week 96 Results from ONCEMRK, A Study Evaluating Once-Daily ISENTRESS\u00ae HD (raltegravir), in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in Appropriate Patients - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-results-from-oncemrk-a-study-evaluating-once-daily-isentress-hd-raltegravir-in-combination-with-other-antiretroviral-agents-for-the-treatment-of-hiv-1-infection-in-a\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Week 96 Results from ONCEMRK, A Study Evaluating Once-Daily ISENTRESS\u00ae HD (raltegravir), in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in Appropriate Patients - Merck.com","og_description":"Once-Daily Version of Raltegravir Now Approved in U.S. and European Union Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of Week 96 results from the pivotal Phase 3 ONCEMRK study evaluating the efficacy and safety of ISENTRESS HD1, a 1200 mg once-daily dose of the company\u2019s integrase inhibitor, ISENTRESS\u00ae (raltegravir), administered orally as two 600 mg film-coated tablets, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg, who are treatment-na\u00efve or whose virus has been suppressed on an initial regimen of ISENTRESS 400 mg given twice daily. Previously, the findings at Week 48 demonstrated that once-daily ISENTRESS HD met its primary efficacy endpoint of non-inferiority to twice-daily ISENTRESS, with a similar safety and tolerability profile. The Week 96 results reaffirm the comparable efficacy and safety of ISENTRESS HD. These study","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-results-from-oncemrk-a-study-evaluating-once-daily-isentress-hd-raltegravir-in-combination-with-other-antiretroviral-agents-for-the-treatment-of-hiv-1-infection-in-a\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:22+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-results-from-oncemrk-a-study-evaluating-once-daily-isentress-hd-raltegravir-in-combination-with-other-antiretroviral-agents-for-the-treatment-of-hiv-1-infection-in-a\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-results-from-oncemrk-a-study-evaluating-once-daily-isentress-hd-raltegravir-in-combination-with-other-antiretroviral-agents-for-the-treatment-of-hiv-1-infection-in-a\/","name":"Merck Announces Week 96 Results from ONCEMRK, A Study Evaluating Once-Daily ISENTRESS\u00ae HD (raltegravir), in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in Appropriate Patients - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-07-24T06:00:00+00:00","dateModified":"2025-11-07T06:26:22+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-results-from-oncemrk-a-study-evaluating-once-daily-isentress-hd-raltegravir-in-combination-with-other-antiretroviral-agents-for-the-treatment-of-hiv-1-infection-in-a\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-results-from-oncemrk-a-study-evaluating-once-daily-isentress-hd-raltegravir-in-combination-with-other-antiretroviral-agents-for-the-treatment-of-hiv-1-infection-in-a\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-results-from-oncemrk-a-study-evaluating-once-daily-isentress-hd-raltegravir-in-combination-with-other-antiretroviral-agents-for-the-treatment-of-hiv-1-infection-in-a\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Week 96 Results from ONCEMRK, A Study Evaluating Once-Daily ISENTRESS\u00ae HD (raltegravir), in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in Appropriate Patients"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"c130a546-7c0e-438a-8364-a39591543002","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Announces-Week-96-Results-from-ONCEMRK-A-Study-Evaluating-Once-Daily-ISENTRESS-HD-raltegravir-in-Combination-with-Other-Antiret-Z61P3.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745518","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745518\/revisions"}],"predecessor-version":[{"id":3674871,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745518\/revisions\/3674871"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745518"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745518"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}